Tacrolimus Assay Comparison: Analytical and Operational Considerations for Immunoassay vs Mass Spectrometry Testing in a High Volume Clinical Laboratory
The Journal of Applied Laboratory Medicine · 2026
DOI: 10.1093/jalm/jfaf199 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Applied Laboratory Medicine, 2026. Verfasst von Rebekah Goldblatt und 3 weiteren Autor:innen. Beteiligte Einrichtung: TriCore Reference Laboratories, Albuquerque, NM, United States. Hauptthemen laut MEDLINE: Tacrolimus, Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Drug Monitoring. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Tacrolimus therapeutic drug monitoring is a routine and critical assay for managing transplant patients. Tacrolimus can be measured from whole blood samples via liquid chromatography–tandem mass spectrometry (LC-MS/MS) or immunoassay (IA). LC-MS/MS provides accurate parent drug quantification with minimal metabolite interference but requires expensive analyzers, highly trained staff, and is often a very manual process. Immunoassays offer faster, simpler workflows, but historically have been prone to significant cross-reaction with the drug’s metabolites or other therapeutic drugs, leading to a falsely elevated result. Newer immunoassays show promising improvements in specificity.
Methods
Using 73 residual patient samples, we compared our in-house LC-MS/MS tacrolimus assay to the Roche Elecsys® tacrolimus electrochemiluminescence immunoassay on the cobas® e801 analyzer. Comparative analysis was done with Deming regression and Bland–Altman comparison. Linearity, within-individual imprecision, and total imprecision post immunoassay implementation were also evaluated, along with changes and improvements to workflow and turnaround times (TAT).
Results
The Roche Elecsys tacrolimus assay correlated well with our LC-MS/MS method (Deming regression equation: y = 1.004x + 0.4848). The bias was 0.52 ng/mL (an average of 8.1%) as determined by Bland–Altman comparison. When switching to the immunoassay we observed a 42%–51% improvement in TAT across the median, 75th percentile, and 90th percentile.
Conclusions
We observed excellent correlation between the Roche Elecsys tacrolimus assay on an e801 analyzer vs our in-house LC-MS/MS assay, with good precision and linearity across reportable ranges. Changing from mass spectrometry to tacrolimus immunoassay substantially improved our TAT and workflow.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- TriCore Reference Laboratories, Albuquerque, NM, United States.
- Department of Pathology, University of New Mexico, Albuquerque, NM, United States.
ORCID-Profile: Melissa M Budelier
Zitieren
APA
Goldblatt, R., Monge, F., Hansen, C., & Budelier, M. M. (2026). Tacrolimus Assay Comparison: Analytical and Operational Considerations for Immunoassay vs Mass Spectrometry Testing in a High Volume Clinical Laboratory. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf199
Vancouver
Goldblatt R, Monge F, Hansen C, Budelier MM. Tacrolimus Assay Comparison: Analytical and Operational Considerations for Immunoassay vs Mass Spectrometry Testing in a High Volume Clinical Laboratory. The Journal of Applied Laboratory Medicine. 2026. doi:10.1093/jalm/jfaf199
BibTeX
@article{Goldblatt2026,
author = {Goldblatt, Rebekah and Monge, Florencia and Hansen, Cory and Budelier, Melissa M},
title = {Tacrolimus Assay Comparison: Analytical and Operational Considerations for Immunoassay vs Mass Spectrometry Testing in a High Volume Clinical Laboratory},
journal = {The Journal of Applied Laboratory Medicine},
year = {2026},
doi = {10.1093/jalm/jfaf199}
}
EUVIMED